EMA Authorised: Synflorix (Pneumococcal polysaccharide serotype 23F;Pneumococcal polysaccharide serotype 4;Pneumococcal polysaccharide serotype 5;Pneumococcal polysaccharide serotype 6B;Pneumococcal polysaccharide serotype 7F;Pneumococcal polysaccharide serotype 9V;Pneumococcal polysaccharide serotype 1;Pneumococcal polysaccharide serotype 14;Pneumococcal polysaccharide serotype 18C;Pneumococcal polysaccharide serotype 19F) — GlaxoSmithKline Biologicals S.A.

View source ↗

Summary

EMA has authorised Synflorix, a pneumococcal conjugate vaccine by GlaxoSmithKline Biologicals S.A., for immunization against multiple pneumococcal serotypes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease
• Pneumococcal Infections

Drugs mentioned

• Synflorix (10-valent pneumococcal conjugate vaccine)

Snippet

Status: Authorised. Therapeutic area: Pneumococcal Infections;Immunization. MAH: GlaxoSmithKline Biologicals S.A.. Decision date: 26/04/2023